nivolumab

Documents about nivolumab

• Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients#300249ClinicalTrials.gov
• Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma#424198ClinicalTrials.gov
• Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma#181757ClinicalTrials.gov
• ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma#835920ClinicalTrials.gov
• A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma#895380ClinicalTrials.gov
• Regorafenib and Nivolumab Simultaneous Combination Therapy#919090ClinicalTrials.gov
• Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)#992355ClinicalTrials.gov
• A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma#847532ClinicalTrials.gov
• An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma#623525ClinicalTrials.gov
• Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma#841725ClinicalTrials.gov
• Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer#847303ClinicalTrials.gov
• Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab#851859ClinicalTrials.gov
• First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)#886490ClinicalTrials.gov
• Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery#373603ClinicalTrials.gov
• A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma#801205ClinicalTrials.gov
• An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia#831912ClinicalTrials.gov
• A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers#851682ClinicalTrials.gov
• A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma#887337ClinicalTrials.gov
• A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer#979697ClinicalTrials.gov
• A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma#329535ClinicalTrials.gov
• Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer#843074ClinicalTrials.gov
• Post-ATU Study of Nivolumab#28315ClinicalTrials.gov
• Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma#967007ClinicalTrials.gov
• An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)#980619ClinicalTrials.gov
• Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer#674901ClinicalTrials.gov
• Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program#152394ClinicalTrials.gov
• Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN#172292ClinicalTrials.gov
• Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome#902867ClinicalTrials.gov
• Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy#993016ClinicalTrials.gov
• Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy#841103ClinicalTrials.gov
• Tinostamustine and Nivolumab in Advanced Melanoma#238094ClinicalTrials.gov
• Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)#145061HAL (France)
• A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS#332734ClinicalTrials.gov
• Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.#840375ClinicalTrials.gov
• First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401#145067HAL (France)
• Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab#369832ClinicalTrials.gov
• An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma#872743ClinicalTrials.gov
• Ipilimumab and Nivolumab in Leptomeningeal Metastases#28298ClinicalTrials.gov
• Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers#234446ClinicalTrials.gov
• Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.#865811ClinicalTrials.gov
• An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors#830528ClinicalTrials.gov
• BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer#831724ClinicalTrials.gov
• Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma#845149ClinicalTrials.gov
• Cryoablation+Ipilimumab+Nivolumab in Melanoma#314334ClinicalTrials.gov
• Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.#327609PubMed
• Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up#465446OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMel#624886HAL (France)
• An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma#683073ClinicalTrials.gov
• Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer#901300ClinicalTrials.gov
• A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC#826361ClinicalTrials.gov